angiotensin IV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-16. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
=== Sweden === In Sweden, a medical license is required before commencing specialty training. Those graduating from Swedish medical schools are first required to do a rotational internship of about 1.5 to 2 years in various specialties before attaining a medical license. The specialist training lasts 5 years.
=== Primary ion source === Three types of ion guns are employed. In one, ions of gaseous elements are usually generated with duoplasmatrons or by electron ionization, for instance noble gases (40Ar+, Xe+), oxygen (16O−, 16O2+, 16O2−), or even ionized molecules such as SF5+ (generated from SF6) or C60+ (fullerene). This type of ion gun is easy to operate and generates roughly focused but high-current ion beams. A second source type, the surface ionization source, generates 133Cs+ primary ions. Caesium atoms vaporize through a porous tungsten plug and are ionized during evaporation. Depending on the gun design, fine focus or high current can be obtained. A third source type, the liquid metal ion gun (LMIG), operates with metals or metallic alloys, which are liquid at room temperature or slightly above. The liquid metal covers a tungsten tip and emits ions under influence of an intense electric field. While a gallium source is able to operate with elemental gallium, recently developed sources for gold, indium, and bismuth use alloys which lower their melting points. The LMIG provides a tightly focused ion beam (<50 nm) with moderate intensity and is additionally able to generate short pulsed ion beams. It is therefore commonly used in static SIMS devices. The choice of the ion species and ion gun respectively depends on the required current (pulsed or continuous), the required beam dimensions of the primary ion beam, and on the sample which is to be analyzed.
In an absorption refrigeration system, thermal energy is used to drive a refrigerant through an absorber–generator solution circuit rather than relying primarily on a mechanical compressor. Absorption refrigeration has a long history: an ammonia–water machine was introduced by Ferdinand Carré in 1859, and lithium bromide–water systems were introduced for industrial applications in the 1950s. The refrigerant evaporates at low pressure and is absorbed into a liquid absorbent. The resulting solution is pumped to a higher pressure and heated in a generator, which separates refrigerant vapour from the solution. The refrigerant then condenses, expands and returns to the evaporator, while the absorbent solution returns to the absorber. Two important working-fluid pairs are ammonia–water, in which ammonia is the refrigerant and water is the absorbent, and water–lithium bromide, in which water is the refrigerant and lithium bromide is the absorbent. The choice of working pair affects operating pressure, temperature range and system performance. Because absorption systems can be driven by thermal energy, they can use sources such as industrial waste heat that might otherwise be rejected to the environment. Their performance and suitability relative to vapor-compression refrigeration depend on the working pair, cycle configuration, heat-source temperature and operating conditions.
Amphetamine, the active ingredient of Adderall, works primarily by increasing the activity of the neurotransmitters dopamine and norepinephrine in the brain. It also triggers the release of several other hormones (e.g., epinephrine) and neurotransmitters (e.g., serotonin and histamine) as well as the synthesis of certain neuropeptides (e.g., cocaine and amphetamine regulated transcript (CART) peptides). Both active ingredients of Adderall, dextroamphetamine and levoamphetamine, bind to the same biological targets, but their binding affinities (that is, potency) differ somewhat. Dextroamphetamine and levoamphetamine are both potent full agonists (activating compounds) of trace amine-associated receptor 1 (TAAR1) and interact with vesicular monoamine transporter 2 (VMAT2), with dextroamphetamine being the more potent agonist of TAAR1. Consequently, dextroamphetamine produces more CNS stimulation than levoamphetamine; however, levoamphetamine has slightly greater cardiovascular and peripheral effects. It has been reported that certain children have a better clinical response to levoamphetamine. In the absence of amphetamine, VMAT2 will normally move monoamines (e.g., dopamine, histamine, serotonin, norepinephrine, etc.) from the intracellular fluid of a monoamine neuron into its synaptic vesicles, which store neurotransmitters for later release (via exocytosis) into the synaptic cleft.
Sources: en.wikipedia.org
Single nucleotide polymorphisms (SNPs) in the MTRR gene impair MTR activity, resulting in elevated homocysteine levels due to compromised methylation to methionine. Elevated homocysteine levels are associated with birth defects in addition to pregnancy complications, cardiovascular disease, cancer, megaloblastic anemia, Alzheimer's diseases and cognitive dysfunction in the elderly. Presence of the mutant variant (66A>G) is associated with significantly lower, up to 4 fold, plasma cobalamin and folate levels in cardiac transplant patients. A consequent decrease in S-adenosylmethionine availability results in DNA hypomethylation. Low folate limits one carbon metabolism and homocysteine metabolism as vitamin B12 interacts with folate in this pathway. Additionally, this mutation is associated with an increased risk in type 2 diabetes.
== Demographics == As of 2018, 360,589 people were enrolled in the Cherokee Nation as citizens. Citizens live in every state, with 2018 populations of 240,417 in Oklahoma, 22,124 in California, 18,406 in Texas, 12,734 in Arkansas, 11,014 in Kansas, and less than 10,000 in each other state. By 2021, enrollment reached 400,000, making the Cherokee Nation the second most populous tribe, closely behind the Navajo Nation. About 140,000 citizens live in the Cherokee Nation reservation area. In 2023, the nation's enrollment reached 450,000. In 2024, the nation released updated demographics maps showing the nation's total population in the United States was approximately 466,118.
=== Power differential DSC === For this kind of setup, also known as Power compensating DSC, the sample and reference crucible are placed in thermally insulated furnaces and not next to each other in the same furnace as in heat-flux-DSC experiments. Then the temperature of both chambers is controlled so that the same temperature is always present on both sides. The electrical power that is required to obtain and maintain this state is then recorded rather than the temperature difference between the two crucibles.
Merck & Co. traces its origins to its former German parent company the Merck Group, which was established by the Merck family in 1668 when Friedrich Jacob Merck purchased a pharmacy in Darmstadt. In 1827, Merck Group evolved from a pharmacy to a drug manufacturer company with the commercial manufacture of morphine. Merck perfected the chemical process of deriving morphine from opium and later introduced cocaine, used to treat sinus problems and to add to beverages to boost energy levels. In 1887 a German-born, long-time Merck employee, Theodore Weicker, went to the United States to represent Merck Group. In 1891, with $200,000 received from E. Merck, Weicker started Merck & Co., with headquarters in lower Manhattan. That year George Merck, the 23-year-old son of the then head of E. Merck (and grandson of the founder) joined Weicker in New York. Merck & Co. operated from 1891 to 1917 as the US subsidiary of the Merck Group.
Within the immune system, prolactin acts to promote lymphocyte differentiation, proliferation, and function through the activation of protein kinase C signaling pathway. Prolactin has immunomodulatory and anti-inflammatory effects within the immune system, contributing to immune system maintenance. Stress also acutely stimulates prolactin production, as dopamine (a prolactin inhibitor) levels are reduced under stress, the pituitary gland is in turn expressed more leading to higher prolactin levels.
Sources: en.wikipedia.org
The 22nd Brigade was deployed as a flank guard, sweeping down the Tanlwe Chaung before hooking around to the Taungup Chaung and ultimately the road to Prome; this move was intended to cut Japanese units to the north off from the Irrawaddy Delta to the south, where most of the key battles were being fought. 1RAR patrolled the area during March and April 1945 and was involved in several contacts. On 20 April it assembled at a point overlooking Tanlwe Chaung, where it was shelled by Japanese artillery and mortars dug in atop two high features to the south. On the morning of 26 April, after a few days of patrols, 1RAR took the lead in what became the Battle of Tanlwe Chaung; after about half an hour of bombing, strafing and artillery bombardment of the Japanese positions, elements of A and D Companies, 1RAR charged up the slopes and routed much of the Japanese garrison before taking both hills. Seven RAR men were killed in the action and 22 were wounded, mostly from D Company; an officer was also injured. An officer of the RAR recalled the battles of April 1945 around Taungup and Tanlwe Chaung as extremely intense:
Due to the difficulty with forming an overcoil, modern watches often use a slightly less effective "dogleg", which uses a series of sharp bends (in plane) to place part of the outermost coil out of the way of the rest of the spring.
===== Cross-presentation ===== When HSPs are extracellular, they can bind to specific receptors on dendritic cells (DC) and promote cross-presentation of their carried peptides. The most important receptors in this case are scavenger receptors, mainly SRECI and LOX-1. CD91 scavenger receptor has been previously proposed as the common HSP receptor. But now its relevance is controversial because the majority of DC types does not express CD91 in relevant amounts and the binding capacity for many HSPs has not been proved. Stimulation of some scavenger receptors can even result in immunosuppression, this is the case for SRA. LOX-1 and SRECI when stimulated guide HSPs with their associated peptides into cross-presentation. LOX-1 binds mainly hsp60 and hsp70. SRECI is now considered to by the common heat-shock protein receptor because it binds hsp60, hsp70, hsp90, hsp110, gp96 and GRP170. The relevance for this type of cross-presentation is high especially in tumour-immunosurveillance. Thanks to the HSP, the bound peptide is protected against degradation in dendritic cell compartments and the efficiency of cross-presentation is higher. Also internalisation of HSP-peptide complex is more efficient than internalisation of soluble antigens. Tumor cells usually express only a few neo-antigens, which can be targeted by immune system and also not all tumor cells express them. Because of that the amount of tumor antigens is restricted and high efficiency of cross-presentation is necessary for mounting strong immune response.
=== Learning arbitrator === Recent research has questioned whether the lateral hypothalamus's role is only restricted to initiating and stopping innate behaviors and argued it learns about food-related cues. Specifically, that it opposes learning about information what is neutral or distant to food. According this view, the lateral hypothalamus is "a unique arbitrator of learning capable of shifting behavior toward or away from important events".
=== Tyler === Tyler considers himself "an ambassador of awesomeness", and is really proud of his beer belly and high school wrestling experience. He bullies Joe and Dylan, with whom he shares his high school dorm, and seems to relish on peeing on things such as his dormmates' door and bed. Miller then decides to match him up with two-time Olympic wrestler Daniel Cormier, who held a perfect MMA record.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.